Have a personal or library account? Click to login
MICB Genetic Variants and Its Protein Soluble Level Are Associated with the Risk of Chronic GvHD and CMV Infection after Allogeneic HSCT Cover

MICB Genetic Variants and Its Protein Soluble Level Are Associated with the Risk of Chronic GvHD and CMV Infection after Allogeneic HSCT

Archivum Immunologiae et Therapiae Experimentalis
Volume 72 (2024): Issue 1 (January 2024)
By:
Open Access
|Jun 2024

Figures & Tables

Fig 1.

MICB genetic variants and development of cGvHD. (a) Donor rs1065056 G allele was less common among patients who developed cGvHD. (b) Donor rs3828903 G allele was more prevalent among recipients lacking cGvHD post-transplantation. cGvHD, chronic graft-versus-host disease; HSCT, hematopoietic stem cell transplantation.
MICB genetic variants and development of cGvHD. (a) Donor rs1065056 G allele was less common among patients who developed cGvHD. (b) Donor rs3828903 G allele was more prevalent among recipients lacking cGvHD post-transplantation. cGvHD, chronic graft-versus-host disease; HSCT, hematopoietic stem cell transplantation.

Fig 2.

Associations between the MICB genotype and the risk of CMV infection development. (a) CMV infection was less frequent in recipients carrying the rs1065075 G allele. (b) Lower incidence of CMV infection in patients transplanted from donors with rs1065075 G allele. CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation.
Associations between the MICB genotype and the risk of CMV infection development. (a) CMV infection was less frequent in recipients carrying the rs1065075 G allele. (b) Lower incidence of CMV infection in patients transplanted from donors with rs1065075 G allele. CMV, cytomegalovirus; HSCT, hematopoietic stem cell transplantation.

Fig 3.

Serum sMICB levels in recipients diagnosed with various post-transplant complications. (a) Increased sMICB concentration in recipients with CMV infection. (b) Higher sMICB level in patients who developed chronic form of GvHD. cGvHD, chronic graft-versus-host disease; CMV, cytomegalovirus; GvHD, graft-versus-host-disease; sMICB, soluble MICB.
Serum sMICB levels in recipients diagnosed with various post-transplant complications. (a) Increased sMICB concentration in recipients with CMV infection. (b) Higher sMICB level in patients who developed chronic form of GvHD. cGvHD, chronic graft-versus-host disease; CMV, cytomegalovirus; GvHD, graft-versus-host-disease; sMICB, soluble MICB.

Fig 4.

Relationships between serum sMICB and two MICB SNPs. (a) Lower sMICB level in serum samples of MICB rs1065057 GG homozygous patients. (b) Differences in sMICB concentration between recipients carrying various MICB rs3828903 genotypes. sMICB, soluble MICB; SNPs, single nucleotide polymorphism.
Relationships between serum sMICB and two MICB SNPs. (a) Lower sMICB level in serum samples of MICB rs1065057 GG homozygous patients. (b) Differences in sMICB concentration between recipients carrying various MICB rs3828903 genotypes. sMICB, soluble MICB; SNPs, single nucleotide polymorphism.

Results of the multivariate analysis for CMV risk factors

VariablesP valueOR95% CI
Age0.59880.99370.9702–1.0176
D/R HLA compatibility0.01420.42760.2144–0.8385
Recipient CMV IgG status<0.000116.25924.8663–76.9165
Donor CMV IgG status0.18840.58340.2570–1.2944
Donor sex0.16061.65620.8250–3.3949
MICB rs1065057 G allele0.02380.47010.2417–0.8988

Serum sMICB concentrations in HSCT recipients

No CMV (pg/mL)CMV [pg/mL]No cGvHD (pg/mL)cGvHD (pg/mL)
Mean67.1396.8562.47116.2
SD54.2372.0449.8877.03
Std. Error8.4712.186.7315.72
25–75% percentile25.38–94.8639.42–129.826.53–88.2571.60–145.2
95% CI50.01–84.2572.10–121.648.98–75.9583.69–148.7

Patients' characteristics

N = 232
Age (years, median, range)50, 18–73
Sex (M/F)135 (58.19%)/97 (41.81%)
Type of donor
  MSD107 (46.12%)
  MUD54 (23.28%)
Haploidentical53 (22.84%)
MMSD17 (7.33%)
Diagnosis
  AML92 (39.66%)
  ALL29 (14.50%)
  MDS25 (12.50%)
  NHL18 (9%)
  MPN17 (8.50%)
  HL10 (5%)
  PCM8 (4%)
  Other33 (16.50%)
Conditioning
  RIC/MAC/NMA104 (44.83%)/125 (53.88%)/3 (1.29%)
Post-transplant complications
  aGvHD (I–IV)91 (39.22%)
  aGvHD (II–IV)48 (20.69%)
  cGvHD46 (19.83%)
  cGvHD de novo/progression of aGvHD to cGvHD/after aGvHD remission17 (36.96%)/8 (17.39%)/20 (43.48%)
  CMV90 (38.79%)
  Relapse31 (13.36%)
  Death30 (12.93%)
No complicationsa83 (35.78%)

Mean serum sMICB concentrations of patients with various MICB genotypes

MICB SNP
Variantrs1065057rs3828903
AA91.47 pg/mL90.45 pg/mL
AG74.95 pg/mL90.48 pg/mL
GG39.78 pg/mL63.49 pg/mL
DOI: https://doi.org/10.2478/aite-2024-0012 | Journal eISSN: 1661-4917
Journal RSS Feed
Language: English
Submitted on: Feb 20, 2024
Accepted on: May 13, 2024
Published on: Jun 7, 2024
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year
Keywords:
MICB,
sMICB,
NK cells,
HSCT,
Post-transplant complications
Related subjects:
Medicine,
Basic medical science,
Biochemistry,
Immunology,
Clinical medicine,
Clinical medicine, other,
Clinical chemistry

© 2024 Jagoda Siemaszko, Marta Dratwa, Agnieszka Szeremet, Maciej Majcherek, Anna Czyż, Małgorzata Sobczyk-Kruszelnicka, Wojciech Fidyk, Iwona Solarska, Barbara Nasiłowska-Adamska, Patrycja Skowrońska, Maria Bieniaszewska, Agnieszka Tomaszewska, Grzegorz W. Basak, Sebastian Giebel, Tomasz Wróbel, Katarzyna Bogunia-Kubik, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 72 (2024): Issue 1 (January 2024)Next article